Efficacy of Probiotic Bacteria (Lactobacillus Reuetri DSM 17938) on Child with Lupus Nephritis

In pediatric patients with Lupus Nephritis (LN), kidney inflammation occurs due to the effects of Systemic Lupus Erythematosus (SLE). Several studies have shown that probiotics can increase the content of beneficial flora and reduce the content of harmful flora in the intestine. This can improve systemic immunity, which will ultimately help improve kidney function. However, research on the administration of probiotics in LN is still very rare, especially the probiotic Lactobacillus reuteri. Assessing the efficacy of probiotic bacteria (lactobasillus reuteri DSM 17938) in influencing the therapeutic response in children with LN. The study design was a randomized controlled trial using urine samples from children with LN. The therapy was monitored for 30 days, divided into two groups: the intervention group, which received standard therapy plus the probiotic Lactobacillus reuteri, and the control group, which received only standard therapy. Analysis showed a significant difference in urine erythrocyte sedimentation (p = 0.045), urine protein/creatinine ratio (p = 0.023), and Renal SLEDAI (p = 0.004) between the intervention and control groups. However, there were no significant differences in urine protein, urine leukocytes, urinary casts, and urine albumin/creatinine ratio. Administration of standard therapy combined with the probiotic Lactobacillus reuteri in children with LN resulted in a significant reduction in the Renal SLEDAI difference, urinary erythrocyte sedimentation rate, and urinary protein/creatinine ratio compared with standard therapy alone. This supports a link between LN and probiotics and has the potential to form the basis for microbiota-based therapeutic interventions.